Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual versus triple therapy in treatment of hepatitis C virus (HCV).

Irish journal of medical science - 1 Jun 2023

Bishai Nevine, Nabawy Walid El, Fiki Mohamed El, Ibrahim Mohamed, Garem Nouman El

Abstract excerpt

BACKGROUND: The goal of HCV treatment is eradication of the virus to prevent complications associated with the disease and decrease all-cause mortality. This work compared sustained viral response (SVR) 12 weeks after end of treatment of chronic HCV patients with different treatment regimens, namely 4 regimens. Two hundred treatment naive chronic HCV patients were selected and divided into 4 equal groups as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C
Share to Hepatitis C, Chronic
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepacivirus

Share to Ribavirin

Share to Sofosbuvir

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 36040651
DOI: 10.1007/s11845-022-03120-9
PMCID: PMC10250505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual versus triple therapy in treatment of hepatitis C virus (HCV).PMID 36040651Read ↗

Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study.Semantic proximity Read ↗

Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.Semantic proximity Read ↗

Update on hepatitis C treatment: systematic review of clinical trials.Semantic proximity Read ↗

The new era of hepatitis C virus therapy.Semantic proximity Read ↗

Advances in hepatitis C therapies.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

A review of standard and newer treatment strategies in hepatitis C.Semantic proximity Read ↗

Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.Semantic proximity Read ↗

Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.Semantic proximity Read ↗

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.Semantic proximity Read ↗

Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.Semantic proximity Read ↗

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.